0001769804
false
0001769804
2023-11-06
2023-11-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): November 6, 2023
AUGMEDIX, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40890 |
|
83-3299164 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
111 Sutter Street, Suite 1300, San Francisco, California 94104
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (888) 669-4885
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, $0.0001 par value per share |
|
AUGX |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02. Results of Operations and Financial Condition.
On
November 6, 2023, Augmedix, Inc., a Delaware corporation (the “Company”), released its financial results for
the third quarter ended September 30, 2023. The press release announcing the release of financial results is furnished as Exhibit 99.1
and is incorporated herein by reference.
The
information provided in this Item 2.02, including Exhibit 99.1, is intended to be “furnished” and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AUGMEDIX,
INC. |
|
|
|
Dated:
November 6, 2023 |
By:
|
/s/
Paul Ginocchio |
|
|
Paul
Ginocchio |
|
|
Chief
Financial Officer |
2
Exhibit 99.1
Augmedix
Delivers 50% Revenue Growth and Expanded Gross Margins for Third Quarter of 2023
SAN
FRANCISCO, November 6, 2023 – Augmedix (Nasdaq: AUGX), a healthcare technology company
that delivers industry-leading ambient medical documentation and data solutions, reported today financial results for the three and nine
months ended September 30, 2023.
“The
third quarter marked another period of strong progress for Augmedix as we continue to be a leader in the large and rapidly growing ambient
medical documentation market,” commented Manny Krakaris, Chief Executive Officer at Augmedix. “Growing adoption of Augmedix
Live and Augmedix Notes drove 50% revenue growth and net revenue retention of 157%, while expanding gross margins by 390 basis points
to 49.5%. With strong revenue growth and improving profitability, we are on track to achieve our financial goals and are increasing our
revenue guidance for 2023 accordingly.”
Continued
Mr. Krakaris, “We are delivering strong financial results while expanding our product portfolio and building out the foundations
of our data and platform strategies. We recently launched early access to Augmedix Go, our fully automated scalable AI medical documentation
solution, and we continue to collaborate closely with HCA Healthcare to launch Augmedix Go for the emergency room setting. We have also
forged strategic relationships with three innovative digital health companies as part of our open network and platform strategy. These
vendor partners will be able to use our delivery platform through application programming interfaces (APIs) so that they and our health
system partners can efficiently benefit and generate incremental ROI from our structured data and bi-directional communication channel
to the point of care.”
“It
is clearer than ever that there is a tremendous opportunity in front of Augmedix,” concluded Mr. Krakaris. “As healthcare
systems lean into our ambient medical documentation technology to reduce the burden on clinicians and enhance operating efficiency, they
are increasingly looking to leverage our structured data for insights and our bi-directional communication channel to deliver vital information
that can effectuate change at the point of care. We are confident that addressing these expanded upstream and downstream requirements
will create greater value for our customers and ultimately, our shareholders.”
Third
Quarter 2023 Financial and Business Highlights
All
comparisons, unless otherwise noted, are to the three months ended September 30, 2022.
| ● | Total
revenue was $11.8 million, an increase of 50% compared to $7.9 million. |
| ● | Dollar-based
Net Revenue Retention was 157% for Health Enterprise customers compared to 130% in the third
quarter of 2022 and 148% in the second quarter of 2023. |
| ● | Average
Clinicians in Service grew 47%. |
| ● | GAAP
Gross Margin increased 390 basis points to 49.5% compared to 45.7%. |
| ● | GAAP
Operating Expenses were $10.2 million, compared to $9.0 million in the third quarter of 2022
and $10.0 million in the second quarter of 2023. |
| ● | GAAP
Net Loss narrowed to $4.4 million compared to $5.5 million. |
| ● | EBITDA
losses declined to $3.7 million compared to $5.0 million. Adjusted EBITDA losses declined
to $3.1 million compared to $4.5 million, which excludes stock-based compensation in both
periods. Adjusted EBITDA losses again declined sequentially from $3.6 million in the second
quarter of 2023. |
| ● | Cash,
cash equivalents, and restricted cash were $22.3 million as of September 30, 2023, compared
to $22.0 million as of December 31, 2022. |
| ● | The
interest only period on our $20 million term loan with SVB was lengthened from January 2024
to July 2024 as we exceeded the financial requirements for extension during the third quarter. |
| ● | Launched
the early access release of Augmedix Go for the clinical setting, a clinician-controlled
mobile app that uses generative AI to create a fully automated draft medical note instantaneously. |
| ● | Established
strategic collaborations with three innovative digital health companies – Myndshft,
Ellipsis Health, and The Sullivan Group – to enhance healthcare enterprise efficiency
and patient outcomes. |
| ● | Hosted
the initial AI Advisory Council meeting with distinguished academics, governance experts,
and customers to provide strategic guidance on Augmedix’s product roadmap on the development
and use of AI. |
| ● | Enhanced
collaboration with HCA Healthcare and Google Cloud to bring generative AI to hospitals. |
| ● | Achieved
certified status by HITRUST for information security, which validates Augmedix’s commitment
to safeguarding sensitive patient information data. |
Non-GAAP
operating expenses, EBITDA and Adjusted EBITDA are a Non-GAAP financial measure. Please see “Non-GAAP Financial Measures”
below and the Reconciliation of the GAAP to Non-GAAP Financial Measures table below.
2023
Revenue Guidance
Augmedix
now expects approximately $44.5 million of revenue in 2023.
Conference
Call
Augmedix
will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Monday, November 6, 2023, to discuss its third quarter 2023 financial results.
The conference call can be accessed by dialing +1-877-407-3982 for U.S. participants or +1-201-493-6780 for international participants
and referencing conference ID #13741543. Interested parties may access a live and archived webcast of the event on the “Investor
Relations” section of the Company’s website at: ir.augmedix.com.
Definition
of Key Metrics
Dollar-Based
Net Revenue Retention: We define a “Health Enterprise” as a company or network of doctors that has at least 50 clinicians
currently employed or affiliated that could utilize our services. Dollar-based net revenue retention is determined as the revenue from
Health Enterprises as of twelve months prior to such period end as compared to revenue from these same Health Enterprises as of the current
period end, or current period revenue. Current period revenue includes any expansion or new products and is net of contraction or churn
over the trailing twelve months but excludes revenue from new Health Enterprises in the current period. We believe growth in dollar-based
net revenue retention is a key indicator of the performance of our business as it demonstrates our ability to increase revenue across
our existing customer base through expansion of users and products, as well as our ability to retain existing customers.
Clinicians
in Service: We define a clinician in service as an individual doctor, nurse practitioner or other healthcare professional using our
services. We average the month-end number of clinicians in service for all months in the measurement
period and the number of clinicians in service at the end of the month immediately preceding the measurement period. We believe
growth in the number of clinicians in service is an indicator of the performance of our business as it demonstrates our ability to penetrate
the market and grow our business.
About
Augmedix
Augmedix
(Nasdaq: AUGX) delivers industry-leading, ambient medical documentation and data solutions to healthcare systems, physician practices,
hospitals, and telemedicine practitioners.
Augmedix
is on a mission to help clinicians and patients form a human connection by seamlessly integrating our technology at the point of care.
Augmedix’s proprietary platform digitizes natural clinician-patient conversations, which are converted into comprehensive medical
notes and structured data in real time. The company’s platform uses automatic speech recognition, and natural language processing,
including large language models, to generate accurate and timely medical notes that are transferred into the EHR.
Augmedix’s
products relieve clinicians of administrative burden, in turn, reducing burnout, increasing clinician efficiency and improving patient
access. Through Augmedix’s proprietary platform and bi-directional communication channel, Augmedix is ideally suited to serve as
the vehicle for change at the point of care.
Augmedix
is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.
Contact
Information
Investors:
Matt
Chesler, CFA
FNK
IR
(646)
809-2183
augx@fnkir.com
investors@augmedix.com
Media:
Kaila
Grafeman
Augmedix
pr@augmedix.com
Non-GAAP
Financial Measures
To
supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP
financial measures: Non-GAAP gross profit, Non-GAAP gross margin, Non-GAAP Operating Expenses, EBITDA, and adjusted EBITDA. The presentation
of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information
prepared and presented in accordance with GAAP.
We
use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons.
We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding
certain items that may not be indicative of our recurring core business operating results. We believe that both management and investors
benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing
future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance and
liquidity as well as comparisons to our competitors’ operating results. We believe these non-GAAP financial measures are useful to investors
both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational
decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our
business.
There
are a number of limitations related to the use of non-GAAP financial measures. We compensate for these limitations by providing specific
information regarding the GAAP amounts excluded from these non-GAAP financial measures and evaluating these non-GAAP financial measures
together with their relevant financial measures in accordance with GAAP.
For
more information on the non-GAAP financial measures, please see the Reconciliation of GAAP to non-GAAP Financial Measures table in this
press release. This accompanying table includes details on the GAAP financial measures that are most directly comparable to Non-GAAP
financial measures and the related reconciliations between these financial measures.
Forward-Looking
Statements
This
press release contains “forward-looking statements” that involve a number of risks and uncertainties. Words such as “believes,”
“may,” “will,” “estimates,” “potential,” “continues,” “anticipates,” “intends,”
“expects,” “could,” “would,” “projects,” “plans,” “targets,” “excited,”
“optimistic,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such
forward-looking statements include, without limitation, statements regarding the
Company’s expectations regarding revenues for the full fiscal year 2023 and the achievement of its financial goals; the ability
of the Company’s vendor and health system partners to efficiently benefit from, and generate incremental ROI through the use of,
the Company’s structured data and bi-directional communication channel to the point of care; the tremendous opportunity in front
of Augmedix; healthcare systems leaning into the Company’s ambient medical documentation technology to reduce the burden on clinicians
and enhance operating efficiency; the increase in healthcare systems looking to leverage the Company’s structured data for insights
and the Company’s bi-directional communication channel to deliver vital information that can effectuate change at the point of
care; and the Company’s confidence that addressing these expanded upstream and downstream requirements will lead to greater value
for its customers and ultimately its shareholders. Our actual results could differ materially from
those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our
most recent Form 10-K filed with the Securities and Exchange Commission on April 17, 2023 as well as other documents that may be filed
by us from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause
results to differ materially from those expressed or implied by such forward-looking statements: our expectations regarding changes in
regulatory requirements; our ability to interoperate with the electronic health record systems of our customers; our reliance on vendors;
our ability to attract and retain key personnel; the competition to attract and retain remote documentation specialists; anticipated
trends, growth rates, and challenges in our business and in the markets in which we operate; our ability to further penetrate our existing
customer base; our ability to protect and enforce our intellectual property protection and the scope and duration of such protection;
developments and projections relating to our competitors and our industry, including competing dictation software providers, third-party,
non-real time medical note generators and real time medical note documentation services; and the impact of current and future laws and
regulations. Past performance is not necessarily indicative of future results. The forward-looking statements included in this press
release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our
views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any
date subsequent to the date of this press release.
AUGMEDIX,
INC.
Condensed
Consolidated Statements of Operations
(Unaudited,
in thousands except EPS and Average Clinicians in Service)
| |
Three Months Ended | |
| |
September 30, | |
| |
(unaudited) | |
| |
2023 | | |
2022 | |
Revenue | |
$ | 11,767 | | |
$ | 7,864 | |
Cost of revenue | |
| 5,937 | | |
| 4,274 | |
Gross profit | |
| 5,830 | | |
| 3,590 | |
Operating Expenses | |
| | | |
| | |
General and administrative | |
| 4,568 | | |
| 4,136 | |
Sales and marketing | |
| 2,729 | | |
| 2,304 | |
Research and development | |
| 2,936 | | |
| 2,608 | |
Total operating expenses | |
| 10,233 | | |
| 9,048 | |
Loss from operations | |
| (4,403 | ) | |
| (5,458 | ) |
| |
| | | |
| | |
Other income (expense), net | |
| (4 | ) | |
| (32 | ) |
Net loss | |
$ | (4,407 | ) | |
$ | (5,490 | ) |
| |
| | | |
| | |
Weighted average common stock outstanding | |
| 45,521 | | |
| 37,427 | |
| |
| | | |
| | |
Earnings Per Share | |
$ | (0.10 | ) | |
$ | (0.15 | ) |
| |
| | | |
| | |
Average Clinicians in Service (CIS) | |
| 1,650 | | |
| 1,121 | |
AUGMEDIX,
INC.
Condensed
Consolidated Balance Sheet
(Unaudited,
in thousands)
| |
September 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Assets | |
| |
Cash, cash equivalents, and restricted cash | |
$ | 22,286 | | |
$ | 21,988 | |
Accounts receivables, net | |
| 9,446 | | |
| 6,354 | |
Other assets | |
| 9,101 | | |
| 5,299 | |
Total assets | |
| 40,833 | | |
| 33,641 | |
| |
| | | |
| | |
Liabilities & Stockholders’ Equity | |
| | | |
| | |
Liabilities | |
| | | |
| | |
Accounts payable | |
$ | 1,816 | | |
$ | 1,563 | |
Deferred revenue | |
| 7,993 | | |
| 7,254 | |
Loan payable | |
| 20,108 | | |
| 15,134 | |
Other liabilities | |
| 10,182 | | |
| 8,224 | |
Total liabilities | |
$ | 40,099 | | |
$ | 32,175 | |
Stockholders’ equity | |
$ | 734 | | |
$ | 1,466 | |
Total liabilities & stockholders’ equity | |
$ | 40,833 | | |
$ | 33,641 | |
AUGMEDIX,
INC.
Condensed
Consolidated Statement of Cash Flows
(Unaudited,
in thousands)
| |
Nine Months Ended | |
| |
September 30, | |
| |
2023 | | |
2022 | |
Cash flows from operating activities | |
$ | (14,468 | ) | |
$ | (12,387 | ) |
Cash flows from investing activities | |
| (1,912 | ) | |
| (816 | ) |
Cash flows from financing activities | |
| 16,989 | | |
| (1,244 | ) |
Effect of exchange rate changes on cash and restricted cash | |
| (311 | ) | |
| (143 | ) |
Net decrease in cash | |
$ | 298 | | |
$ | (14,590 | ) |
Cash, restricted cash, and cash equivalents at the beginning of the period | |
$ | 21,988 | | |
$ | 41,587 | |
Cash, restricted cash, and cash equivalents at the end of the period | |
$ | 22,286 | | |
$ | 26,997 | |
AUGMEDIX,
INC.
Reconciliation
of GAAP to Non-GAAP Financial Measures
(Unaudited,
in thousands)
| |
Three Months Ended | |
| |
September 30, | |
| |
(unaudited) | |
| |
2023 | | |
2022 | |
Stock Based Compensation Expense | |
| | |
| |
Cost of revenue | |
$ | 33 | | |
$ | 22 | |
General and administrative | |
| 425 | | |
| 320 | |
Sales and marketing | |
| 57 | | |
| 50 | |
Research and development | |
| 122 | | |
| 85 | |
Total stock-based compensation expense | |
$ | 637 | | |
$ | 477 | |
| |
| | | |
| | |
Net loss | |
$ | (4,407 | ) | |
$ | (5,490 | ) |
Interest | |
| 355 | | |
| 257 | |
Tax | |
| 84 | | |
| 19 | |
Depreciation | |
| 252 | | |
| 217 | |
EBITDA | |
$ | (3,716 | ) | |
$ | (4,997 | ) |
Add: Stock-based compensation | |
| 637 | | |
| 477 | |
Adjusted EBITDA | |
$ | (3,079 | ) | |
$ | (4,520 | ) |
| |
| | | |
| | |
GAAP Cost of revenue | |
$ | 5,937 | | |
$ | 4,274 | |
Less: Stock-based compensation | |
| 33 | | |
| 22 | |
Non-GAAP cost of revenue | |
$ | 5,904 | | |
$ | 4,252 | |
| |
| | | |
| | |
Non-GAAP Gross Profit | |
$ | 5,863 | | |
$ | 3,612 | |
Non-GAAP Gross Margin | |
| 49.8 | % | |
| 45.9 | % |
| |
| | | |
| | |
GAAP Operating expenses | |
$ | 10,233 | | |
$ | 9,048 | |
Less: Stock-based compensation | |
| 604 | | |
| 455 | |
Non-GAAP operating expenses | |
$ | 9,629 | | |
$ | 8,593 | |
9
v3.23.3
Cover
|
Nov. 06, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 06, 2023
|
Entity File Number |
001-40890
|
Entity Registrant Name |
AUGMEDIX, INC.
|
Entity Central Index Key |
0001769804
|
Entity Tax Identification Number |
83-3299164
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
111 Sutter Street
|
Entity Address, Address Line Two |
Suite 1300
|
Entity Address, City or Town |
San Francisco
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94104
|
City Area Code |
888
|
Local Phone Number |
669-4885
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.0001 par value per share
|
Trading Symbol |
AUGX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Augmedix (NASDAQ:AUGX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Augmedix (NASDAQ:AUGX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024